The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
629 reports and counting
Graphite Bio Raises $238M in Series B
Graphite Bio, a Biotech company based in 279 East Grand Avenue, South San Francisco, CA 94080, has raised $238M in Series B at a $1B valuation led by ARCH Venture Partners, Vida Ventures, Norwest Venture Partners, Samsara BioCapital.
Insitro Raises $400M in Series D
Insitro, a Biotech company based in 279 East Grand Avenue, South San Francisco, CA 94080, has raised $400M in Series D at a $2.8B valuation led by Blackstone, Canada Pension Plan Investment Board, Arch Venture Partners, Foresite Capital, GV, Andreessen Horowitz.
East West Bank Raises $10B in Public
East West Bank, a Banking company based in 135 North Los Robles Avenue, Pasadena, CA 91101, has raised $10B in Public at a $12B valuation led by Public.
Graphite Bio raises $238M Series B at $1B valuation
Graphite Bio raises $238M in Series B at $1B valuation. Precision genetic medicines...
Insitro raises $400M Series D at $2.8B valuation
Insitro raises $400M in Series D at $2.8B valuation. Machine learning for drug discovery...
Freenome raises $290M Series D at $1.1B valuation
Freenome raises $290M in Series D at $1.1B valuation. AI-driven early cancer detection...
East West Bank raises $10B Public at $12B valuation
East West Bank raises $10B in Public at $12B valuation. Bank subsidiary...
Allogene Therapeutics Raises $325M in Series E
Allogene Therapeutics, a Biotech company based in 210 East Grand Avenue, South San Francisco, CA 94080, has raised $325M in Series E at a $3.9B valuation led by TPG, Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.
Where is SaaS Company 279's Headquarters? Main Office Location
SaaS Company 279's global headquarters is located at 279 Tech Drive, Atlanta, GA 90278. The office serves as the central hub for the company's SaaS operations.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.